Works matching IS 00071048 AND DT 2022 AND VI 198 AND IP 3

Results: 30
    1

    Erratum.

    Published in:
    2022
    Publication type:
    Correction Notice
    2

    Corrigendum.

    Published in:
    2022
    Publication type:
    Correction Notice
    3

    GOALs in relapsed DLBCL.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 3, p. 419, doi. 10.1111/bjh.18296
    By:
    • Rösler, Wiebke;
    • Zenz, Thorsten
    Publication type:
    Article
    4
    5

    Retention of functional mitochondria in mature red blood cells from patients with sickle cell disease.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 3, p. 574, doi. 10.1111/bjh.18287
    By:
    • Moriconi, Chiara;
    • Dzieciatkowska, Monika;
    • Roy, Micaela;
    • D'Alessandro, Angelo;
    • Roingeard, Philippe;
    • Lee, June Young;
    • Gibb, David R.;
    • Tredicine, Maria;
    • McGill, Marlon A.;
    • Qiu, Annie;
    • La Carpia, Francesca;
    • Francis, Richard O.;
    • Hod, Eldad A.;
    • Thomas, Tiffany;
    • Picard, Martin;
    • Akpan, Imo J.;
    • Luckey, Chance John;
    • Zimring, James C.;
    • Spitalnik, Steven L.;
    • Hudson, Krystalyn E.
    Publication type:
    Article
    6
    7
    8
    9
    10
    11

    Minimal residual disease and imaging‐guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 3, p. 515, doi. 10.1111/bjh.18249
    By:
    • Böckle, David;
    • Tabares, Paula;
    • Zhou, Xiang;
    • Schimanski, Sven;
    • Steinhardt, Maximilian J.;
    • Bittrich, Max;
    • Seebacher, Elena;
    • Ulbrich, Maria;
    • Wilnit, Amy;
    • Metz, Corona;
    • Heidemeier, Anke;
    • Bley, Thorsten;
    • Werner, Rudolf;
    • Buck, Andreas;
    • Einsele, Hermann;
    • Kortüm, K. Martin;
    • Beilhack, Andreas;
    • Rasche, Leo
    Publication type:
    Article
    12
    13
    14
    15
    16

    Characteristics, management and outcome of acquired amegakaryocytic thrombocytopenia.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 3, p. 595, doi. 10.1111/bjh.18235
    By:
    • Roeser, Anais;
    • Moulis, Guillaume;
    • Ebbo, Mikael;
    • Terriou, Louis;
    • Poullot, Elsa;
    • Lioger, Bertrand;
    • Chilles, Marie;
    • Labussière‐Wallet, Helene;
    • Mausservey, Christelle;
    • Pha, Micheline;
    • Puyade, Mathieu;
    • Cheze, Stephane;
    • Limal, Nicolas;
    • Michel, Marc;
    • Godeau, Bertrand;
    • Mahévas, Matthieu
    Publication type:
    Article
    17
    18
    19
    20
    21

    VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome‐negative B‐precursor acute lymphoblastic leukaemia in first relapse.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 3, p. 523, doi. 10.1111/bjh.18218
    By:
    • Heraudet, Luc;
    • Galtier, Jean;
    • Favre, Simon;
    • Peyraud, Florent;
    • Cazaubiel, Titouan;
    • Leroy, Harmony;
    • Mottal, Nathan;
    • Gros, François‐Xavier;
    • Forcade, Edouard;
    • Clément, Laurence;
    • Dumas, Pierre‐Yves;
    • Pigneux, Arnaud;
    • Leguay, Thibaut
    Publication type:
    Article
    22
    23

    A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 3, p. 492, doi. 10.1111/bjh.18209
    By:
    • Kuhnl, Andrea;
    • Roddie, Claire;
    • Kirkwood, Amy A.;
    • Tholouli, Eleni;
    • Menne, Tobias;
    • Patel, Amit;
    • Besley, Caroline;
    • Chaganti, Sridhar;
    • Sanderson, Robin;
    • O'Reilly, Maeve;
    • Norman, Jane;
    • Osborne, Wendy;
    • Bloor, Adrian;
    • Lugthart, Sanne;
    • Malladi, Ram;
    • Patten, Piers E. M.;
    • Neill, Lorna;
    • Martinez‐Cibrian, Nuria;
    • Kennedy, Hannah;
    • Phillips, Elizabeth H.
    Publication type:
    Article
    24
    25

    A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 3, p. 535, doi. 10.1111/bjh.18193
    By:
    • Adès, Lionel;
    • Duployez, Nicolas;
    • Guerci‐Bresler, Agnes;
    • Laribi, Kamel;
    • Peterlin, Pierre;
    • Vey, Norbert;
    • Thepot, Sylvain;
    • Wickenhauser, Stefan;
    • Zerazhi, Hacene;
    • Stamatoullas, Aspassia;
    • Wattel, Eric;
    • Recher, Christian;
    • Toma, Andrea;
    • Dimicoli‐Salazar, Sophie;
    • Braun, Thorsten;
    • Beyne‐Rauzy, Odile;
    • Marolleau, Jean‐Pierre;
    • Cheze, Stéphane;
    • Park, Sophie;
    • Cluzeau, Thomas
    Publication type:
    Article
    26
    27

    A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 3, p. 482, doi. 10.1111/bjh.18161
    By:
    • Hess, Georg;
    • Hüttmann, Andreas;
    • Witzens‐Harig, Mathias;
    • Dreyling, Martin H.;
    • Keller, Ulrich;
    • Marks, Reinhard;
    • Ernst, Thomas;
    • Pott, Christiane;
    • Viardot, Andreas;
    • Frontzek, Fabian;
    • Trautmann, Marcel;
    • Ruckes, Christian;
    • Deuster, Oliver;
    • Rosenwald, Andreas;
    • Theobald, Matthias;
    • Lenz, Georg
    Publication type:
    Article
    28
    29
    30

    Issue Information.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 3, p. 409, doi. 10.1111/bjh.17597
    Publication type:
    Article